EssilorLuxottica delivered historic double-digit revenue growth (up 11.2%) for 2025, largely driven by sales of Ray-Ban Meta glasses and myopia-management solutions.
The group sold more than seven million Ray-Ban Meta glasses and its myopia management portfolio was up by 22% in revenue worldwide, with the US market forecast to get off to a strong start with Stellest lens’ FDA approval coming through in November 2025. Overall, the full year sales growth was €28.5 billion (about NZ$56.1 billion) at constant exchange rate, with Q4 reaching record growth of 18.4%.
“In an uncertain macroeconomic and geopolitical environment and despite headwinds from US tariffs, we reached record earnings, while making bold investments to advance our innovation agenda,” said Francesco Milleri, chair and CEO, and Paul du Saillant, deputy CEO, of EssilorLuxottica.
